biostudies-literatureBogani GNCI NIH HHS226-234https://www.ebi.ac.uk/biostudies/studies/S-EPMC9445918biostudies-literatureUnknown162(1)Serous endometrial cancer represents a relative rare entity accounting for about 10% of all diagnosed endometrial cancer, but it is responsible for 40% of endometrial cancer-related deaths. Patients with serous endometrial cancer are often diagnosed at earlier disease stage, but remain at higher risk of recurrence and poorer prognosis when compared stage-for-stage with endometrioid subtype endometrial cancer. Serous endometrial cancers are characterized by marked nuclear atypia and abnormal p53 staining in immunohistochemistry. The mainstay of treatment for newly diagnosed serous endometrial cancer includes a multi-modal therapy with surgery, chemotherapy and/or radiotherapy. Unfortunately, despite these efforts, survival outcomes still remain poor. Recently, The Cancer Genome Atlas (TCGA)Gynecologic oncologyUterine serous carcinoma.PMC9445918P30 CA016042P30 CA008748Takehara KSegev YBogani GMorice PLopez SNgoi NYLRaspagliesi FEnomoto TVaughan MMConcin NTakano MKim SIPanici PBScambia GBini MSagae SMariani ALeitao MMMonk BJCandido Dos Reis FJPignata SIndini ALorusso DDenys HRay-Coquard IMuzii LProvencher DPoka RWimberger PDi Donato VNout RAColombo NfalseUterine serous carcinoma.Serous endometrial cancer represents a relative rare entity accounting for about 10% of all diagnosed endometrial cancer, but it is responsible for 40% of endometrial cancer-related deaths. Patients with serous endometrial cancer are often diagnosed at earlier disease stage, but remain at higher risk of recurrence and poorer prognosis when compared stage-for-stage with endometrioid subtype endometrial cancer. Serous endometrial cancers are characterized by marked nuclear atypia and abnormal p53 staining in immunohistochemistry. The mainstay of treatment for newly diagnosed serous endometrial cancer includes a multi-modal therapy with surgery, chemotherapy and/or radiotherapy. Unfortunately, despite these efforts, survival outcomes still remain poor. Recently, The Cancer Genome Atlas (TCGA)2021-01-01T00:00:00Z2021 Jul2025-05-29T16:11:38.664Z2025-04-04T09:32:24.998ZS-EPMC94459183393484810.1016/j.ygyno.2021.04.029